文献速递头颈MR

治疗前MRI影像组学可评估局部晚期鼻咽癌不同诱导化疗方案的疗效反应

Pretreatment MRI-Derived Radiomics May Evaluate the Response of Different Induction Chemotherapy Regimens in Locally advanced Nasopharyngeal Carcinoma.
PubMed 文献 · Acad Radiol · 2020-09-29

回顾性纳入265例病理确诊的局部晚期鼻咽癌(II-IV期)患者,其中GP组115例、TP组150例,从3T多序列MRI提取影像组学特征并建立预测诱导化疗早期反应的模型。GP组联合T1、T2、T1C序列的影像组学标签准确率在训练队列为0.852、验证队列为0.853,高于TP组的0.774和0.727;GP模型AUC在训练队列达0.907(95%CI 0.843-0.970),验证队列为0.886(95%CI 0.772-0.998),TP组分别为0.800(95%CI 0.712-0.888)和0.863(95%CI 0.758-0.967)。

要点

  • 治疗前多序列MRI影像组学可预测局部晚期鼻咽癌诱导化疗早期反应。
  • GP方案模型的鉴别效能优于TP方案,AUC在训练队列为0.907。
  • 临床因素在反应组与非反应组间均无显著差异(所有p>0.05)。

核心结论

  • 治疗前MR影像组学标签对GP方案诱导化疗早期反应的预测优于TP方案,可能有助于指导诱导化疗管理。

研究设计与样本

  • 回顾性纳入265例病理确诊的局部晚期鼻咽癌(II-IV期)患者,其中GP组115例、TP组150例。
  • 从3T扫描仪多MR序列勾画的感兴趣区提取影像组学特征。
  • 随机分层分组为训练队列和验证队列,基于所选特征行逻辑回归,分别建立GP与TP方案影像组学标签与诱导化疗早期反应的关联。

诊断标准与关键数值

  • GP组联合T1、T2、T1C序列所选特征的影像组学标签准确率:训练队列0.852,验证队列0.853。
  • TP组影像组学标签准确率:训练队列0.774,验证队列0.727,低于GP组。
  • GP模型区分反应者与非反应者的AUC:训练队列0.907(95%CI 0.843-0.970),验证队列0.886(95%CI 0.772-0.998)。
  • TP组AUC:训练队列0.800(95%CI 0.712-0.888),验证队列0.863(95%CI 0.758-0.967)。

临床应用与阅片要点

  • 治疗前可基于多序列MRI提取影像组学特征,用于预测局部晚期鼻咽癌患者对GP或TP方案诱导化疗的早期反应。
  • GP方案模型的预测效能更稳定,阅片时可关注联合T1、T2、T1C序列的影像组学标签输出。
  • 临床因素在反应组与非反应组间无显著差异(所有p>0.05),模型判断主要依赖影像组学特征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To evaluate and compare the performance of radiomics in predicting induction chemotherapy response treated with two different regimens in patients with advanced nasopharyngeal carcinoma.

MATERIALS AND METHODS: A total of 265 patients with pathologically confirmed locally advanced nasopharyngeal carcinoma (stage II-IV), including 115 treated with gemcitabine plus cisplatin (GP group) and 150 treated with docetaxel plus cisplatin (TP group) were retrospectively enrolled. Radiomics features were extracted from the volume of interest delineated in multi-MR sequences on a 3T scanner. After random stratified grouping (training and validation cohorts) and logistic regression based on selected features, the association between the radiomics signature and the early response to induction chemotherapy were established for GP and TP regiments, respectively.

RESULTS: Clinical factors showed no significant difference between the response and non-response groups for the GP and TP regiments (all p > 0.05). The accuracy of the radiomics signature consisting of selected features from the joint T1, T2, and T1C in the GP group (0.852 in the training cohort vs. 0.853 in the validation cohort) was significantly higher than that in the TP group (0.774 vs 0.727). The overall performance of the GP model was steady, with efficiency to distinguish responders from nonresponders with an AUC reaching 0.907 (95% confidence interval [CI] [0.843-0.970]) in the training cohort and 0.886 (95% CI [0.772-0.998]) in the validation cohort, while leveling at 0.800 (95% CI [0.712-0.888]) in the training cohort and 0.863 (95% CI [0.758-0.967]) in the validation cohort in the TP group.

CONCLUSION: Pretreatment MR radiomics signature can better predict the early response to IC in the GP regimen than the TP regimen, which may be helpful to guide IC management.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Zhang L, Ye Z, Ruan L, et al. Pretreatment MRI-Derived Radiomics May Evaluate the Response of Different Induction Chemotherapy Regimens in Locally advanced Nasopharyngeal Carcinoma. Acad Radiol. 2020. PMID: 33004261. doi:10.1016/j.acra.2020.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。